These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Myeloperoxidase-ANCA IgG induces different forms of small vessel vasculitis based on type of synergistic immune stimuli. Hu P; Xiao H; Alba MA; Atkins HM; Gou S; Hu Y; Gomez JC; Jania CM; Martin JR; Morrison TE; Tilley SL; Heise MT; Doerschuk CM; Falk RJ; Jennette JC Kidney Int; 2024 Nov; 106(5):870-886. PubMed ID: 39216658 [TBL] [Abstract][Full Text] [Related]
27. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Kallenberg CG; Heeringa P; Stegeman CA Nat Clin Pract Rheumatol; 2006 Dec; 2(12):661-70. PubMed ID: 17133251 [TBL] [Abstract][Full Text] [Related]
29. Serum levels of interleukin-32 and interleukin-6 in granulomatosis with polyangiitis and microscopic polyangiitis: association with clinical and biochemical findings. Krajewska Wojciechowska J; Kościelska-Kasprzak K; Krajewski W; Morawski K Eur Cytokine Netw; 2019 Dec; 30(4):151-159. PubMed ID: 32096477 [TBL] [Abstract][Full Text] [Related]
30. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis. Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW Clin Exp Rheumatol; 2017; 35 Suppl 103(1):111-118. PubMed ID: 28339364 [TBL] [Abstract][Full Text] [Related]
33. L31. A GWAS in ANCA-associated vasculitis: will genetics help re-define clinical classification? Lyons PA; Smith KG Presse Med; 2013 Apr; 42(4 Pt 2):589-91. PubMed ID: 23490642 [No Abstract] [Full Text] [Related]
34. Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation. Ohlsson S; Holm L; Hansson C; Ohlsson SM; Gunnarsson L; Pettersson Å; Skattum L PLoS One; 2019; 14(6):e0218272. PubMed ID: 31216309 [TBL] [Abstract][Full Text] [Related]
35. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Cornec D; Cornec-Le Gall E; Fervenza FC; Specks U Nat Rev Rheumatol; 2016 Oct; 12(10):570-9. PubMed ID: 27464484 [TBL] [Abstract][Full Text] [Related]
36. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. Kallenberg CG; Rarok A; Stegeman CA; Limburg PC Autoimmun Rev; 2002 Feb; 1(1-2):61-6. PubMed ID: 12849060 [TBL] [Abstract][Full Text] [Related]
37. Analytical and diagnostic accuracy of the EliA automated enzyme fluoroimmunoassay for antineutrophil cytoplasmic autoantibody detection. Villalta D; Tonutti E; Tampoia M; Bizzaro N; Papisch W; Tozzoli R; Stella S Clin Chem Lab Med; 2004; 42(10):1161-7. PubMed ID: 15552276 [TBL] [Abstract][Full Text] [Related]
38. Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Talor MV; Stone JH; Stebbing J; Barin J; Rose NR; Burek CL Clin Exp Immunol; 2007 Oct; 150(1):42-8. PubMed ID: 17614969 [TBL] [Abstract][Full Text] [Related]
39. The role of tobacco smoking in anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic review. Moretti M; Elefante E; Pisapia L; Di Cianni F; Italiano N; La Rocca G; Talarico R; Mosca M; Baldini C; Ferro F Clin Exp Rheumatol; 2024 Jul; 42(7):1321-1332. PubMed ID: 38976289 [TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U; Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]